Corteva, Inc.

AI-generated fair value estimate for this company.

Method: 10-year unlevered FCF DCF on standalone crop-protection business post Vylor spin-off: ~$1.6B estimated FY2026 segment EBITDA annualized from 1H2026 results ($3.73B revenue, $776M EBITDA), 45% FCF conversion for a ~$720M normalized FCF base; 4% FCF growth years 1-5; 3% years 6-10; 9% discount rate; 2.5% terminal growth; ~$3.0B estimated allocated net debt; 667.20M shares outstanding.

Reasoning: Corteva separated its seed/genetics business into Vylor Inc. on October 1, 2026, leaving CTVA as a pure-play crop-protection chemicals company with a much smaller, less-diversified earnings base and limited standalone financial history, so a DCF built from the most recent segment-level results (rather than legacy consolidated figures) with a higher discount rate for the added concentration and integration risk is the most defensible approach.